Biomimesys
Retrospective HCS Pharma 2022
We are glad starting a new Year! But nothing better than assessing what happened along the last one to glance back at the road traveled so far… and looking forward to what’s next!
Biomimesys
Animal tests no longer necessary before drug clinical trials? Let’s make it in 3D in preclinical studies… and with the extracellular matrix!
End of last year, the american legislation has ratified that new drugs no longer need to be tested in animals to receive Food and Drug Administration (FDA) approval. This is a huge step toward animal-free validation of drugs, but it requires the design of a relevant and more predictive drug Read more…
Biomimesys
Organ-on-chips including BIOMIMESYS® for toxicology and oncology programmes
Industry and academia are increasingly complexifying their in vitro models, not only 3D models but also organs-on-chip (OoC) in their studies. Such systems are needed for putting different tissues into contact, or to take into account flux-related aspects. BIOMIMESYS® being an ideal hydroscaffold™ for 3D cell culture, this webinar aims Read more…
Biomimesys
Feedback to the first OncoLille Days Congress
The first edition of OncoLille Days congress took place from November 2th to 4th, 2022 in Lille. All 3 days were very rich in interesting presentations about interdisciplinary research in oncology, including biology, mathematics, human sciences, etc. Our project leader Véronique De Conto was pleased to present her poster about Read more…
Biomimesys
Meet us at ESTIV congress in Barcelona (21-25 November 2022)
We are pleased to participate to the 21st International Congress of the European Society of Toxicology In Vitro (ESTIV 2022), which will take place in Barcelona-Sitges, Spain, from 21st to 25th November 2022. Our project Leader in in vitro pharmacology Véronique De Conto will present her poster entitled “In vitro microenvironment modifies the neurotoxic Read more…
Biomimesys
De retour de l’INEM sur le stand Dominique Dutscher – HCS Pharma
Nous avons eu le plaisir d’être invités par notre distributeur Dutscher, et en particulier par Romain Guegan, à présenter lors de la journée Necker-Imagine organisée à l’INEM (Institut Necker Enfants Malades) le 3 novembre dernier. Elodie a eu l’occasion de présenter aux chercheurs présents notre technologie BIOMIMESYS® pour une culture Read more…
Biomimesys
Meet us in OncoLille Days 2022 where we present a poster about matricial tumoral microenvironment in 3D in vitro models
We are pleased to participate in the first OncoLille Days congress from November 2th to 4th, 2022. Inaugurated on October 12th, 2022, OncoLille Institute aims at developing an interdisciplinary research in oncology, including biology, physics, microtechnologies, chemistry, mathematics, bioinformatics, statisitcs, health technologies and social and human sciences. HCS Pharma collaborates Read more…
Biomimesys
HCS Pharma @ CellME in Berlin
Our project leader Méryl and our CBO Mathieu are currently attending CellME (Cell Manufacturing & Engineering) Forum taking place these days in Berlin, Germany. Méryl had the chance to present his work and the advantages of BIOMIMESYS® for organoid culture earlier today: Please feel free to discuss with them on Read more…
Biomimesys
Welcome to Gaspard in HCS Pharma
We are glad to announce the arrival of Gaspard in our team! Gaspard Delpouve obtained his Diploma of Advanced Technician in Biotechnologies in Lille in 2018, and in 2019 he passed a Bachelor’s degree in health biotechnologies at the University of Nantes. During his studies he completed several internships in Read more…
Biomimesys
Feedback of Natacha’s internship about the matrix remodeling in Parkinson’s disease: an in vitro study
This is the end of the 6-month internship of Natacha in HCS Pharma, about the microenvironment modifications in Parkinson’s disease. Indeed, in vivo studies in the literature showed that the neuronal death in Parkinson’s disease involved Extracellular Matrix (ECM) modifications, including an increase in some components like collagen and a Read more…
Biomimesys
Meet us at EUSAAT 2022 in Linz (Austria) to understand how to reduce animal testing
Our project director Elodie is participating to EUSAAT congress in Linz (Austria) this week, the European Congress on Alternatives to Animal Testing. She will have the pleasure to present our work aiming at bridging the gap between in vivo and in vitro situations by taking into account the extracellular matrix Read more…
Biomimesys
Looking forward to EUSAAT congress
Next month, we will have the pleasure to participate in the 23rd EUSAAT (EUropean Society for Alternative to Animal Testing) congress, which will take place in Linz (Austria) on the 26th-28th of September. We have proposed an abstract about how we use 3D in vitro cell culture models for recapitulating Read more…
Biomimesys
Feedback to the Federation of European Neuroscience Societies (FENS) forum
The Federation of European Neuroscience Societies (FENS) forum 2022 took place in Paris, from 9 to 15 July. This event gathers nearly 8,000 neuroscientists from 92 countries. Twenty-two plenary and special lectures were given in 8 conferences room, about various topics in neurosciences, like brain imaging methods, brain development (synapse Read more…
Biomimesys
Meet us in the Federation of European Neurosciences Societies (FENS) congress, from 9 to 13 July in Paris
Our project leader in in vitro pharmacology Veronique De Conto will be present to the Federation of European Neurosciences Societies (FENS) congress, from 9 to 13 July in Paris. She will present a poster about the importance of microenvironment in cerebral in vitro models for phenotypic screening, in the frame Read more…
Biomimesys
Using BIOMIMESYS® Oncology in cancer research, results and future possibilities
Solid tumors are associated with a modified microenvironment, in particular an enhanced collagen content and increased stiffness at the level of the extracellular matrix (ECM). These ECM changes are now recognized as important drivers of cancer initiation, progression, and propagation, and also impact the responses of cancerous cells to treatments. Read more…
HCS, HCA & Biology
The link between extracellular matrix and aging skin
Human skin is largely composed of a collagen-rich connective tissue, which provides structural and functional support. This connective tissue which is the dermal extracellular matrix (ECM) produced, organized, and maintained by dermal fibroblasts and confers strength and resiliency to skin. In young skin, fibroblasts produce and adhere to the dermal Read more…
Biomimesys
Matrix stiffness: a key feature in cancer progression
Increased ExtraCellular Matrix (ECM) stiffness is a common process in many cancers (Pickup et al, 2014). This process influences the behaviour of cancer cells in the tumour microenvironment. The accumulation of ECM in the stroma is mainly due to a high production of ECM molecules by TGF-β(Transforming Growth Factor-beta) -stimulated Read more…
Biomimesys
The extracellular matrix and inflammation
The extracellular matrix (ECM) is an integral component of all organs and plays a pivotal role in tissue homeostasis and repair. ECM actively supports and maintains the dynamic interplay between tissue compartments as well as embedded resident and recruited inflammatory cells in response to pathologic stimuli. The inflammation process involves Read more…
Biomimesys
Cellular structures in BIOMIMESYS® hydroscaffold using Scanning electron microscopy (SEM): example of liver cells
Scanning Electron Microscopy (EM) has been an indispensable tool for Biological sciences. A great challenge was propelled by the need to find methods to better preserve and analyze structures at a state closest to the native state. With BIOMIMESYS® hydroscaffold technology, we have developed a new method to use SEM Read more…
Biomimesys
HCS Pharma était présent au Workshop OoC 2022 (article in french)
HCS Pharma était présent au Workshop OoC pour une création et une structuration de la filière, organisé par Biovalley à l’Institut Pierre-Gilles de Gennes (Paris). Nous sommes très heureux d’avoir pu sponsoriser l’événement, mais aussi tout simplement d’y avoir participé – en présentiel – et de pouvoir discuter avec des chercheurs Read more…
HCS, HCA & Biology
The role of hyaluronic acid in the skin
Hyaluronic acid (HA) is a linear polymer in which a simple disaccharide is repeated thousands of time, thereby creating a huge hydrophilic molecule that confers a large volume of hydration and contributes to the turgor and flexibility of healthy skin. HA is dynamically produced by most skin cells, not only Read more…
Biomimesys
Importance of the microenvironment in cerebral in vitro models for phenotypic screening (Abstract of Veronique’s thesis)
About 90% of drug candidates fail in clinical trials, for efficacy- and toxicity-related reasons, which often involve the Central Nervous System (CNS). This high failure rate highlights a lack of relevance in experimental models used upstream, including human in vitro models. Indeed, they do not take into account the complexity Read more…
Biomimesys
Weldone for successfully completing your PhD, Véronique!
2022 is beginning, but 2021 ended in the most beautiful way… with Véronique De Conto‘s PhD defense. She successfully defended her PhD thesis about the importance of the microenvironment in cerebral in vitro models for phenotypic screening. We had the privilege to maintain the PhD defense on-site, even if one member Read more…